{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-022305","form_type":"8-K","ticker":"GCTK","cik":"0001506983","company_name":"Glucotrack, Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.584809+00:00","generated_at":"2026-05-16T20:19:19.950048+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Glucotrack reports Q3 net loss of $4.2M; cash $7.9M to fund through Q1 2026; IDE submission Spring 2026","bullets":["Q3 2025 net loss $4.2M ($4.64 per share) vs $5.1M in Q3 2024; nine-month net loss $15.8M.","Cash and equivalents $7.9M at Sep 30, 2025; expected to fund operations through first quarter 2026.","Secured $3M convertible note ($3.6M principal) and $20M ELOC; proceeds to repay note and eliminate warrant dilution.","IDE submission for CBGM to FDA expected Spring 2026; long-term feasibility study initiated in Australia."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-022305","json":"https://secwatch.observer/filing/0001493152-25-022305.json","markdown":"https://secwatch.observer/filing/0001493152-25-022305.md","text":"https://secwatch.observer/filing/0001493152-25-022305.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506983/000149315225022305/0001493152-25-022305-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506983/000149315225022305/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:19:19.950048+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}